Hosted on MSN
FDA layoffs and priority review voucher programme’s lapse disrupt rare disease pipeline
Against the stark backdrop of the FDA job cuts, stakeholders in the rare disease space find themselves facing heightened uncertainty. In late March 2025, the Trump administration moved forward with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback